Brainstorm Cell Therapeutics Inc. (BCLI)
NASDAQ: BCLI · Real-Time Price · USD
1.260
+0.010 (0.80%)
Nov 20, 2024, 4:00 PM EST - Market closed
BCLI Stock Forecast
BCLI's stock price has decreased by -53.33% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for BCLI stock has a target of 30, which predicts an increase of 2,280.95% from the current stock price of 1.26.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jul 11, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for BCLI is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $30 | Hold → Strong Buy | Upgrades | $30 | +2,280.95% | Jul 11, 2024 |
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Sep 28, 2023 |
| Maxim Group | Maxim Group | Strong Buy Maintains $75 → $150 | Strong Buy | Maintains | $75 → $150 | +11,804.76% | Mar 31, 2023 |
| Maxim Group | Maxim Group | Hold → Strong Buy Upgrades n/a | Hold → Strong Buy | Upgrades | n/a | n/a | Feb 5, 2021 |
| Maxim Group | Maxim Group | Strong Buy Maintains $120 → $135 | Strong Buy | Maintains | $120 → $135 | +10,614.29% | Aug 17, 2017 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.63
from -6.00
EPS Next Year
-2.51
from -2.63
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.43 | -1.71 | -1.26 | ||
| Avg | -2.63 | -2.51 | -2.30 | ||
| Low | -2.79 | -3.23 | -3.23 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.